ArticlePLoS neglected tropical diseases2015
International external quality assessment study for molecular detection of Lassa virus.
Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.PLoS neglected tropical diseases · 2021Pooled it
- Lassa Fever in Travelers from West Africa, 1969-2016.Emerging infectious diseases · 2019Pooled it
- Evaluation of antigen and antibody assays for surveillance of Lassa virus in peri-domestic rodents in southeastern Sierra Leone: a cross-sectional study.The Lancet. Microbe · 2025Article
- Reservoir displacement by an invasive rodent reduces Lassa virus zoonotic spillover risk.Nature communications · 2024Article
- Metagenomic surveillance uncovers diverse and novel viral taxa in febrile patients from Nigeria.Nature communications · 2023Article
- Lassa Virus Genetics.Current topics in microbiology and immunology · 2023Article
- Lassa Virus Countermeasures.Current topics in microbiology and immunology · 2023Article
- Lassa Virus Replicon Particle Vaccine Protects Strain 13/N Guinea Pigs Against Challenge With Geographically and Genetically Diverse Viral Strains.The Journal of infectious diseases · 2022Article
- Article
- Genome Sequences of Five Arenaviruses from Pygmy Mice (Mus minutoides) in Sierra Leone.Microbiology resource announcements · 2022Article
- Validation of Inactivation Methods for Arenaviruses.Viruses · 2021Article
- Article
- ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge.NPJ vaccines · 2021Article
- Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak.Scientific reports · 2020Article
- Article
- A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.mBio · 2020Article
- Review
- Lassa fever diagnostics: past, present, and future.Current opinion in virology · 2019Review
- Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1-May 6, 2018.Emerging infectious diseases · 2019Article
- Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak.Science (New York, N.Y.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lassa virus (LASV) is a causative agent of hemorrhagic fever in West Africa. In recent years, it has been imported several times to Europe and North America. The method of choice for early detection of LASV in blood is RT-PCR. Therefore, the European Network for Diagnostics of 'Imported' Viral Diseases (ENIVD) performed an external quality assessment (EQA) study for molecular detection of LASV. A proficiency panel of 13 samples containing various concentrations of inactivated LASV strains Josiah, Lib-1580/121, CSF, or AV was prepared. Samples containing the LASV-related lymphocytic choriomeningitis virus (LCMV) and negative sera were included as specificity controls. Twenty-four laboratories from 17 countries (13 European, one African, one Asian, two American countries) participated in the study. Thirteen laboratories (54%) reported correct results, 4 (17%) laboratories reported 1 to 2 false-negative results, and 7 (29%) laboratories reported 3 to 5 false-negative results. This EQA study indicates that most participating laboratories have a good or acceptable performance in molecular detection of LASV. However, several laboratories need to review and improve their diagnostic procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.